Showing results (821-830 of 3,636) with videos related to

Sort By:
Pageof 364
Breast (Edinburgh, Scotland)|September 25, 2024
A systematic review and meta-analysis of risk factors influencing patient-reported arm symptoms post-breast cancer treatment: Accounting for radiotherapy impactYuqin Liang, Yuedan Zhou, Ruud Houben, et al.
Breast (Edinburgh, Scotland)|May 14, 2025
Effect of AI-based pre-hospital health education via QR code on APAIS scores in patients with breast nodules: A retrospective studyGuozhen Ma, Chuyuan Miao, Pengjun Jiang, et al.
Breast (Edinburgh, Scotland)|May 11, 2025
Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinomaYoung-Won Lee, Sae-Byul Lee, Il Yong Chung, et al.
Breast (Edinburgh, Scotland)|May 18, 2025
Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (-) metastatic breast cancer patients in Korea (KCSG BR21-15)Jieun Lee, Dae-Won Lee, Min Hwan Kim, et al.
Breast (Edinburgh, Scotland)|April 26, 2025
Current pattern of care in radiation therapy for DCIS in Australia and New Zealand - where are we heading?Adam Ofri, Sze Ki Melanie Tam, Suki Gill, et al.
Breast (Edinburgh, Scotland)|April 26, 2025
Options for postoperative radiation therapy in patients with de novo metastatic breast cancerChaofan Li, Yusheng Wang, Biyun Fang, et al.
Breast (Edinburgh, Scotland)|April 18, 2025
Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world studyYouzhao Ma, Mingda Zhu, Jingyang Zhang, et al.
Breast (Edinburgh, Scotland)|April 4, 2025
Self-reported cognitive function in older breast cancer survivors after chemotherapy treatmentRachel Kim, Julia Peña, Kai-Ping Liao, et al.
Breast (Edinburgh, Scotland)|March 16, 2025
Identifying germline pathogenic variants in breast cancer using tumor sequencingMara Cruellas, Andri Papakonstantinou, Adrià López-Fernández, et al.
Breast (Edinburgh, Scotland)|March 6, 2025
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
Pageof 364